BACKGROUND: Increased sexual risk behaviour in participants enrolled in HIV prevention trials has been a concern. The HVTN 503/Phambili study, a phase 2B study of the Merck Ad-5 multiclade HIV vaccine in South Africa, suspended enrollment and vaccinations following the results of the Step study. Participants were notified of their treatment allocation and continue to be followed. We investigated changes in risk behaviour over time and assessed the impact of study unblinding. METHODS:801 participants were enrolled. Risk behaviours were assessed with an interviewer-administered questionnaire at 6-month intervals. We assessed change from enrolment to the first 6-month assessment pre-unblinding and between enrolment and at least 6 months post-unblinding on all participants with comparable data. A one-time unblinding risk perception questionnaire was administered post-unblinding. RESULTS: A decrease in participants reporting unprotected sex was observed in both measured time periods for men and women, with no differences by treatment arm. At 6 months (pre-unblinding), 29.6% of men and 35.8% of women reported changing from unprotected to protected sex (p<0.0001 for each). Men (22%) were more likely than women (14%) to report behaviour change after unblinding (p=0.009). Post-enrolment, 142 (45%) of 313 previously uncircumcised men underwent medical circumcision. 663 participants completed the unblinding questionnaire. More vaccine (24.6%) as compared to placebo recipients (12.0%) agreed that they were more likely to get HIV than most people (p<0.0001), and attributed this to receiving the vaccine. CONCLUSION: We did not find evidence of risk compensation during this clinical trial. Some risk behaviour reductions including male circumcision were noted irrespective of treatment allocation.
RCT Entities:
BACKGROUND: Increased sexual risk behaviour in participants enrolled in HIV prevention trials has been a concern. The HVTN 503/Phambili study, a phase 2B study of the Merck Ad-5 multiclade HIV vaccine in South Africa, suspended enrollment and vaccinations following the results of the Step study. Participants were notified of their treatment allocation and continue to be followed. We investigated changes in risk behaviour over time and assessed the impact of study unblinding. METHODS: 801 participants were enrolled. Risk behaviours were assessed with an interviewer-administered questionnaire at 6-month intervals. We assessed change from enrolment to the first 6-month assessment pre-unblinding and between enrolment and at least 6 months post-unblinding on all participants with comparable data. A one-time unblinding risk perception questionnaire was administered post-unblinding. RESULTS: A decrease in participants reporting unprotected sex was observed in both measured time periods for men and women, with no differences by treatment arm. At 6 months (pre-unblinding), 29.6% of men and 35.8% of women reported changing from unprotected to protected sex (p<0.0001 for each). Men (22%) were more likely than women (14%) to report behaviour change after unblinding (p=0.009). Post-enrolment, 142 (45%) of 313 previously uncircumcised men underwent medical circumcision. 663 participants completed the unblinding questionnaire. More vaccine (24.6%) as compared to placebo recipients (12.0%) agreed that they were more likely to get HIV than most people (p<0.0001), and attributed this to receiving the vaccine. CONCLUSION: We did not find evidence of risk compensation during this clinical trial. Some risk behaviour reductions including male circumcision were noted irrespective of treatment allocation.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Beryl A Koblin; Kenneth H Mayer; Elizabeth Noonan; Ching-Yun Wang; Michael Marmor; Jorge Sanchez; Stephen J Brown; Michael N Robertson; Susan P Buchbinder Journal: J Acquir Immune Defic Syndr Date: 2012-08-01 Impact factor: 3.731
Authors: Glenda E Gray; Mary Allen; Zoe Moodie; Gavin Churchyard; Linda-Gail Bekker; Maphoshane Nchabeleng; Koleka Mlisana; Barbara Metch; Guy de Bruyn; Mary H Latka; Surita Roux; Matsontso Mathebula; Nivashnee Naicker; Constance Ducar; Donald K Carter; Adrien Puren; Niles Eaton; M Julie McElrath; Michael Robertson; Lawrence Corey; James G Kublin Journal: Lancet Infect Dis Date: 2011-05-11 Impact factor: 25.071
Authors: Jeffrey N Martin; Michelle E Roland; Torsten B Neilands; Melissa R Krone; Joshua D Bamberger; Robert P Kohn; Margaret A Chesney; Karena Franses; James O Kahn; Thomas J Coates; Mitchell H Katz Journal: AIDS Date: 2004-03-26 Impact factor: 4.177
Authors: Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson Journal: Lancet Date: 2008-11-13 Impact factor: 79.321
Authors: Jonathan E Volk; Nancy A Hessol; Glenda E Gray; James G Kublin; Gavin J Churchyard; Koleka Mlisana; Maphoshane Nchabeleng; Susan P Buchbinder; Linda-Gail Bekker Journal: Int J STD AIDS Date: 2013-10-08 Impact factor: 1.359
Authors: Branwen N Owen; Jocelyn Elmes; Romain Silhol; Que Dang; Ian McGowan; Barbara Shacklett; Edith M Swann; Ariane van der Straten; Rebecca F Baggaley; Marie-Claude Boily Journal: J Int AIDS Soc Date: 2017-01-12 Impact factor: 5.396
Authors: Andrew N Phillips; Valentina Cambiano; Fumiyo Nakagawa; Deborah Ford; Jens D Lundgren; Edith Roset-Bahmanyar; François Roman; Thierry Van Effelterre Journal: PLoS One Date: 2014-09-10 Impact factor: 3.240
Authors: Masunga K Iseselo; Edith A M Tarimo; Eric Sandstrom; Asli Kulane Journal: Int J Environ Res Public Health Date: 2020-10-01 Impact factor: 3.390